ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,596.80
0.36%
S&P ASX All Technology
2,978.80
0.34%
Brent Oil
83.975
0.52%
US Dollar vs AUD
1.52991
-0.07%
Bitcoin
57,362.81
-1.50%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. CytoSorbents Corporation (CTSO)

  7. CytoSorbents Corporation (CTSO) News

CTSO CytoSorbents Corporation

0.8407
0.0307 (3.79%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
CytoSorbents Corporation CTSO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.0307 3.79% 0.8407 06:30:00
Open Price Low Price High Price Close Price Previous Close
0.81 0.81 0.8642 0.8407 0.81
more quote information »

Recent News

Date Time Source Heading
26/4/202421:00GLOBECytoSorbents to Report First Quarter 2024 Operating and..
17/4/202421:00GLOBESTAR-T Pivotal Trial Results to Be Featured as a..
06/3/202423:00GLOBECytoSorbents to Report Fiscal 2023 Operating and Financial..
08/2/202423:00GLOBECytoSorbents to Present at the TD Cowen 44th Annual Health..
18/1/202409:20EDGAR2Form 8-K - Current report
17/1/202423:15GLOBEGroundbreaking Randomized Controlled Trial Reports Excellent..
09/1/202407:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
29/12/202308:49EDGAR2Form 8-K - Current report
28/12/202323:00GLOBECytoSorbents Provides Update on the STAR-T Trial and Reports..
16/12/202308:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202301:15EDGAR2Form 8-K - Current report
14/12/202301:15GLOBECytoSorbents Announces Closing of $10.3 Million Registered..
12/12/202308:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/12/202308:10EDGAR2Form 8-K - Current report
10/11/202308:20EDGAR2Form 8-K - Current report
10/11/202308:15GLOBECytoSorbents Reports Third Quarter 2023 Financial and..
10/11/202308:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/10/202322:00GLOBECytoSorbents to Report Third Quarter 2023 Operating and..
05/10/202322:00GLOBECytoSorbents to Present at the 8th Annual Dawson James..
27/9/202322:15EDGAR2Form 8-K - Current report
27/9/202321:00GLOBECytoSorbents Highlights Upcoming Presentations at EACTS..
21/9/202323:35GLOBEDawson James Securities Announces October Date for 8th..
21/9/202306:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202306:30EDGAR2Form 8-K - Current report
19/9/202321:00GLOBECytoSorbents Announces Kathleen P. Bloch To Resume as..
13/9/202306:31EDGAR2Form 8-K - Current report
12/9/202301:32GLOBECytoSorb with Ex Vivo Organ Perfusion: Transforming the..
02/9/202306:43GLOBECytoSorbents Announces Resignation of Chief Financial..
02/9/202306:30EDGAR2Form 8-K - Current report
31/8/202321:00GLOBECytoSorbents Granted Expanded ANVISA Registration to Treat..
16/8/202307:57EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/8/202321:00PRNUSCytoSorbents Completes U.S. and Canadian STAR-T Pivotal..
12/8/202307:30EDGAR2Form 8-K - Current report
09/8/202310:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202306:15GLOBECytoSorbents Reports Second Quarter 2023 Financial and..
02/8/202306:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26/7/202321:00GLOBECytoSorbents to Report Second Quarter 2023 Operating and..
20/7/202307:19EDGAR2Form 8-K - Current report
12/7/202310:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202310:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202310:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202310:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202310:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Your Recent History

NASDAQ
CTSO
CytoSorbents
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved